Elevar Says Lirafugratinib Added to NCCN Guidelines as Second-Line Therapy

Elevar Therapeutics says lirafugratinib (Lyrfigtu) was added to NCCN Guidelines as a second-line therapy for cholangiocarcinoma with FGFR2 fusion or other rearrangement.